EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management

Harendran Elangovan, Rohit Loomba, Mark Muthiah, Jörn Schattenberg, Ming Hua Zheng, Mazen Noureddin, Christos Mantzoros, Jacob George

Clinical and Molecular Hepatology · 2026

DOI: 10.3350/cmh.2025.0857 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Harendran Elangovan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia. Hauptthemen laut MEDLINE: Incretins, Metabolic Diseases, Kidney Diseases, Liver Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: University of Sydney, National Health and Medical Research Council, MRFF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Steatotic liver disease (SLD) is a leading cause of disease globally and demands new therapeutic approaches to mitigate underlying metabolic dysregulation. Incretin-based therapies are emerging as a viable prospect to fulfil this unmet niche. A literature review to inform the evidence base for incretin focussed pharmacology in the metabolic liver diseases space and an informed commentary on unmet areas of need. Incretin-based therapeutics demonstrate multifarious benefits across the chronic metabolic disease spectrum with promising data across the continuum of pathology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsMetabolic DiseasesKidney DiseasesLiver DiseasesHeart DiseasesHumansChronic DiseaseLiverCardiovascular DiseasesFatty LiverDipeptidyl-Peptidase IV Inhibitors

Stichwörter der Autor:innen

CKLMGIPGLP-1GlucagonIncretinsMAFLDMASH

Substanzen

IncretinsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Westmead, NSW, Australia.
  • MASLD Research Center, University of California San Diego, San Diego, CA, USA.
  • Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
  • Saarland University Medical Center, University of the Saarland, Homburg, Germany and PharmaScienceHub (PSH), Saarbrücken, Germany.
  • MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • Division of Gastroenterology and Hepatology, Houston Methodist Hospital, Houston, TX, USA.

Förderung

  • University of Sydney
  • National Health and Medical Research Council
  • MRFF
  • Cancer Institute, NSW
  • Boston Scientific Corporation
  • Olympus Medical
  • Roche and Astellas
  • Ansh Inc

Zitieren

APA

Elangovan, H., Loomba, R., Muthiah, M., Schattenberg, J., Zheng, M. H., Noureddin, M., Mantzoros, C., & George, J. (2026). Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.0857

Vancouver

Elangovan H, Loomba R, Muthiah M, Schattenberg J, Zheng MH, Noureddin M, et al. Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.0857

BibTeX
@article{Elangovan2026,
  author = {Elangovan, Harendran and Loomba, Rohit and Muthiah, Mark and Schattenberg, Jörn and Zheng, Ming Hua and Noureddin, Mazen and Mantzoros, Christos and George, Jacob},
  title = {Incretin-based therapies for cardio-kidney-liver-metabolic disease: the role of the liver in the modern era of chronic disease management},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  doi = {10.3350/cmh.2025.0857}
}
Kostenlos starten →